• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia: A systematic review of longitudinal studies.第七届世界口腔医学研讨会:口腔白斑病的预后生物标志物:纵向研究的系统评价。
Oral Dis. 2019 Jun;25 Suppl 1(Suppl 1):64-78. doi: 10.1111/odi.13087.
2
World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia and proliferative verrucous leukoplakia-A systematic review of retrospective studies.第七届世界口腔医学研讨会:口腔白斑病和增殖性疣状白斑病的预后生物标志物——回顾性研究的系统评价。
Oral Dis. 2021 May;27(4):848-880. doi: 10.1111/odi.13363. Epub 2020 May 12.
3
Malignant transformation of oral leukoplakia: a systematic review of observational studies.口腔白斑的恶性转化:观察性研究的系统评价
J Oral Pathol Med. 2016 Mar;45(3):155-66. doi: 10.1111/jop.12339. Epub 2015 Jul 20.
4
[Oral medicine 8. Leukoplakia of the oral mucosa].[口腔医学8.口腔黏膜白斑病]
Ned Tijdschr Tandheelkd. 2013 Jul-Aug;120(7-8):384-90.
5
Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review.组织生物标志物预测诊断为口腔白斑病患者口腔癌风险:系统评价。
Oral Dis. 2021 Nov;27(8):1977-1992. doi: 10.1111/odi.13747. Epub 2021 Feb 2.
6
Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers.联合生物标志物预测口腔白斑病患者恶变风险的列线图。
Oral Oncol. 2017 Sep;72:132-139. doi: 10.1016/j.oraloncology.2017.07.015. Epub 2017 Jul 20.
7
[Molecular risk markers for malignant transformation of oral mucosal leukoplakia ].[口腔黏膜白斑恶变的分子风险标志物]
Vopr Onkol. 2012;58(3):327-32.
8
Optimal Management of Proliferative Verrucous Leukoplakia: A Systematic Review of the Literature.增殖性疣状白斑的优化管理:文献系统评价
Otolaryngol Head Neck Surg. 2015 Oct;153(4):504-11. doi: 10.1177/0194599815586779. Epub 2015 Jun 4.
9
[Leukoplakia and erythroplakia--two orale precursor lesions].[白斑和红斑——两种口腔前驱病变]
Laryngorhinootologie. 2009 Oct;88(10):666-72; quiz 673-5. doi: 10.1055/s-0029-1241184. Epub 2009 Oct 7.
10
Marked variation in malignant transformation rates of oral leukoplakia.口腔白斑恶变率存在显著差异。
Evid Based Dent. 2015 Dec;16(4):102-3. doi: 10.1038/sj.ebd.6401128.

引用本文的文献

1
Hallmarks of Cancer Expression in Oral Leukoplakia: A Scoping Review of Systematic Reviews and Meta-Analyses.口腔白斑中癌症表达的特征:系统评价与荟萃分析的范围综述
Cancers (Basel). 2025 Jul 22;17(15):2427. doi: 10.3390/cancers17152427.
2
[Progress in clinicopathological diagnosis of oral potentially malignant disorders].[口腔潜在恶性疾病的临床病理诊断进展]
Hua Xi Kou Qiang Yi Xue Za Zhi. 2025 Jun 1;43(3):314-324. doi: 10.7518/hxkq.2025.2024427.
3
Significance of Epidermal Growth Factor Receptor (EGFR) upregulation in the prediction of the malignant transformation risk in oral potentially malignant disorders: a systematic review and meta-analysis.表皮生长因子受体(EGFR)上调在预测口腔潜在恶性疾病恶变风险中的意义:一项系统评价与荟萃分析
Front Oral Health. 2025 Mar 27;6:1578561. doi: 10.3389/froh.2025.1578561. eCollection 2025.
4
Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).头颈部皮肤鳞状细胞癌的转移模式与治疗选择(综述)
Mol Clin Oncol. 2024 Apr 24;20(6):40. doi: 10.3892/mco.2024.2739. eCollection 2024 Jun.
5
Biomarkers of malignant transformation in oral leukoplakia: from bench to bedside.口腔白斑病恶性转化的生物标志物:从基础到临床。
J Zhejiang Univ Sci B. 2023 May 13;24(10):868-882. doi: 10.1631/jzus.B2200589.
6
Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research.口腔白斑中免疫组化标志物CD138和CD43的比较:一项原创研究
J Pharm Bioallied Sci. 2023 Jul;15(Suppl 1):S209-S212. doi: 10.4103/jpbs.jpbs_454_22. Epub 2023 Jul 5.
7
Comparison of Immunohistochemical Markers in Oral Submucous Fibrosis and Oral Submucous Fibrosis Transformed to Oral Squamous Cell Carcinoma-A Systematic Review and Meta-Analysis.口腔黏膜下纤维性变和口腔黏膜下纤维性变转化为口腔鳞状细胞癌的免疫组织化学标志物比较:系统评价和荟萃分析。
Int J Mol Sci. 2023 Jul 21;24(14):11771. doi: 10.3390/ijms241411771.
8
Salivary miRNAs Expression in Potentially Malignant Disorders of the Oral Mucosa and Oral Squamous Cell Carcinoma: A Pilot Study on miR-21, miR-27b, and miR-181b.唾液微小RNA在口腔黏膜潜在恶性疾病及口腔鳞状细胞癌中的表达:关于miR-21、miR-27b和miR-181b的一项初步研究
Cancers (Basel). 2022 Dec 31;15(1):291. doi: 10.3390/cancers15010291.
9
Follow-up study of veterans with white and red oral mucosal lesions at Veterans Affairs Dental Clinics.退伍军人事务部牙科诊所中患有白色和红色口腔黏膜病变的退伍军人的随访研究。
Clin Exp Dent Res. 2023 Feb;9(1):82-92. doi: 10.1002/cre2.677. Epub 2022 Dec 12.
10
Podoplanin Expression Independently and Jointly with Oral Epithelial Dysplasia Grade Acts as a Potential Biomarker of Malignant Transformation in Oral Leukoplakia.足突蛋白表达与口腔上皮异型增生分级独立并共同作用,可作为口腔白斑恶变的潜在生物标志物。
Biomolecules. 2022 Apr 19;12(5):606. doi: 10.3390/biom12050606.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis.口腔潜在恶性疾病的患病率:系统评价和荟萃分析。
J Oral Pathol Med. 2018 Aug;47(7):633-640. doi: 10.1111/jop.12726. Epub 2018 Jun 6.
3
Clinical features and presentation of oral potentially malignant disorders.口腔潜在恶性疾病的临床特征与表现
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):582-590. doi: 10.1016/j.oooo.2018.03.011. Epub 2018 Apr 4.
4
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.口腔黏膜表皮生长因子受体酪氨酸激酶与口腔癌的化学预防
J Natl Cancer Inst. 2018 Mar 1;110(3):250-7. doi: 10.1093/jnci/djx186.
5
Oral potentially malignant disorders: risk of progression to malignancy.口腔潜在恶性疾病:进展为恶性肿瘤的风险
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):612-627. doi: 10.1016/j.oooo.2017.12.011. Epub 2017 Dec 29.
6
Predictive value of the combination of SMAD4 expression and lymphocyte infiltration in malignant transformation of oral leukoplakia.SMAD4表达与淋巴细胞浸润联合检测对口腔白斑恶变的预测价值
Cancer Med. 2017 Apr;6(4):730-738. doi: 10.1002/cam4.1005. Epub 2017 Mar 3.
7
Leukoplakia-A Diagnostic and Management Algorithm.白斑——一种诊断与管理算法
J Oral Maxillofac Surg. 2017 Apr;75(4):723-734. doi: 10.1016/j.joms.2016.10.012. Epub 2016 Oct 26.
8
p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia.p53和ki67作为口腔白斑化学预防反应判定中的生物标志物。
J Oral Pathol Med. 2017 May;46(5):346-352. doi: 10.1111/jop.12498. Epub 2016 Sep 8.
9
HERG1 potassium channel expression in potentially malignant disorders of the oral mucosa and prognostic relevance in oral squamous cell carcinoma.HERG1钾通道在口腔黏膜潜在恶性疾病中的表达及在口腔鳞状细胞癌中的预后相关性
Head Neck. 2016 Nov;38(11):1672-1678. doi: 10.1002/hed.24493. Epub 2016 Apr 30.
10
Expression of the voltage-gated potassium channel Kv3.4 in oral leucoplakias and oral squamous cell carcinomas.电压门控钾通道Kv3.4在口腔白斑和口腔鳞状细胞癌中的表达。
Histopathology. 2016 Jul;69(1):91-8. doi: 10.1111/his.12917. Epub 2016 Feb 28.

第七届世界口腔医学研讨会:口腔白斑病的预后生物标志物:纵向研究的系统评价。

World Workshop on Oral Medicine VII: Prognostic biomarkers in oral leukoplakia: A systematic review of longitudinal studies.

机构信息

Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.

Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts.

出版信息

Oral Dis. 2019 Jun;25 Suppl 1(Suppl 1):64-78. doi: 10.1111/odi.13087.

DOI:10.1111/odi.13087
PMID:31140698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6544170/
Abstract

OBJECTIVE

To identify the prognostic biomarker candidates for stratification and long-term surveillance of oral leukoplakia progressing to cancer via a systematic literature review.

MATERIALS AND METHODS

Systematic searches with no date restrictions were conducted on March 29, 2018, targeting the databases PubMed (Ovid), EMBASE (Ovid), EBM (Ovid), and Web of Science (ISI). Bias was assessed using the Quality in Prognosis Studies tool. Biomarkers were stratified based on hallmarks of cancer.

RESULTS

Inclusion criteria were met by 25 of 3,415 studies. A range of biomarkers were evaluated experimentally for risk stratification, prognosis, and surveillance of oral leukoplakia in tissue, blood, and saliva. However, the studies were highly heterogeneous and require further validation. Biomarkers reported in these studies included inflammatory or oxidative markers, growth factors, ion channels, genetic and cellular regulatory factors, and epigenetic biomarkers. Studies tended to include small sample sizes, under-reported or variably reported histopathological data, did not address potential confounding, reported limited/variable follow-up data, or lacked a control group. Inclusion of subsets from chemoprevention trials may have introduced bias regarding reported malignant transformation rates and accuracy of prognostic biomarkers.

CONCLUSIONS

This review identified insufficient longitudinal evidence to support validated prognostic biomarkers for oral leukoplakia. Further studies are needed to identify molecular targets with the potential to mitigate risk of malignant transformation.

摘要

目的

通过系统文献回顾,确定用于口腔白斑癌变风险分层和长期监测的预后生物标志物候选物。

材料和方法

无日期限制的系统搜索于 2018 年 3 月 29 日在数据库 PubMed(Ovid)、EMBASE(Ovid)、EBM(Ovid)和 Web of Science(ISI)上进行。使用预后研究质量工具评估偏倚。根据癌症特征对生物标志物进行分层。

结果

符合纳入标准的研究有 3415 项中的 25 项。在组织、血液和唾液中,对多种生物标志物进行了风险分层、预后和口腔白斑监测的实验评估。然而,这些研究高度异质,需要进一步验证。这些研究中报告的生物标志物包括炎症或氧化标志物、生长因子、离子通道、遗传和细胞调节因子以及表观遗传生物标志物。研究往往样本量小,组织病理学数据报告不足或可变,未解决潜在的混杂因素,报告的随访数据有限/可变,或缺乏对照组。化学预防试验的亚组纳入可能会对报告的恶性转化率和预后生物标志物的准确性产生偏倚。

结论

本综述确定了用于口腔白斑的经充分验证的预后生物标志物的证据不足。需要进一步的研究来确定具有减轻恶性转化风险潜力的分子靶标。